Suchergebnisse - "Breccia, Massimo"

PubPharm (132)

31

Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia : the impact of age and long-term follow-up

enthalten in: Leukemia & lymphoma | 2021

von Scalzulli, E. | Colafigli, G. | Pepe, S. | +8

32

Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor : a phase 1b study

enthalten in: Leukemia & lymphoma | 2021

von Ottmann, O. | Stegelmann, F. | Breccia, M. | +4

33

Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

enthalten in: Expert review of hematology | 2021

von Efficace, F. | Vignetti, M. | Sparano, F. | +2

34

Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors : a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)

enthalten in: Annals of hematology | 2021

von Breccia, M. | Celant, S. | Olimpieri, P. | +19

35

Ruxolitinib discontinuation syndrome : incidence, risk factors, and management in 251 patients with myelofibrosis

enthalten in: Blood cancer journal | 2021

von Palandri, F. | Palumbo, G. | Elli, E. | +33

36

Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia : Is it time to introduce it in the clinical practice?

enthalten in: Critical reviews in oncology/hematology | 2021

von Colafigli, G. | Scalzulli, E. | Di Prima, A. | +6

37

Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

enthalten in: Clinical drug investigation | 2020

von Serrao, A. | Scalzulli, E. | Fiori, L. | +3

38

On the road to treatment-free remission in chronic myeloid leukemia : what about 'the others'?

enthalten in: Expert review of anticancer therapy | 2020

von Stagno, F. | Breccia, M. | Di Raimondo, F.

39

Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia : a critical review of the current practice

enthalten in: Expert review of hematology | 2020

von Breccia, M. | Efficace, F. | Colafigli, G. | +4

40

Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs

enthalten in: American journal of hematology | 2020

von Iurlo, A. | Cattaneo, D. | Malato, A. | +14